Navigation Links
Sangamo Announces Public Offering of Common Stock
Date:4/7/2011

RICHMOND, Calif., April 7, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it is offering to sell 6,700,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Barclays Capital Inc. is the sole book-running manager in this offering and Sangamo will grant the underwriter a thirty (30) day option to purchase up to 1,005,000 additional shares.

The securities described above are being offered by Sangamo pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on June 16, 2009. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the preliminary prospectus supplement relating to these securities may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone: 888-603-5847).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. San
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
2. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
4. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
6. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
7. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
8. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Global Stem Cells Group ... the company’s first cellular and regenerative medicine symposium in ... day, hands-on stem cell training class Oct. 10. The ... M.D., President of Therapeutic Confrontations (CONFTERA) in Barcelona. ... in regenerative medicine and recent advances in cellular therapies, ...
(Date:5/26/2015)... Texas , May 26, 2015  A simple ... Health Science Center to detect early Alzheimer,s disease is ... adults. Detailed standardized guidelines that are needed ... have been published in Alzheimer,s & Dementia . ... of an international working group that includes UNT Health ...
(Date:5/26/2015)... ANGELES , 26. mája 2015 ... v mene svojej rodiny prezidentom Barackovi Obamovi a ... v súvislosti so stratou Dr. Rongxiang Xu ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol ... dobe a jeho odhodlanie v oblasti vedy a ...
(Date:5/26/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... company,s Phase IIb trial of ORMD-0801, its oral insulin ... The submission was made under the company,s existing Investigational ... study of ORMD-0801 for type 2 diabetics is designed ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... N.J. , Feb. 5 Amicus Therapeutics (Nasdaq: ... John F. Crowley as Chairman of the Board in ... immediately.  Mr. Crowley will succeed Donald J. Hayden, Jr. , ... "The Board,s decision to elect Mr. Crowley as Chairman of the ...
... chronic wounds can be deadly to maggot ,biosurgeons, used ... journal Microbiology . The findings could lead to ... novel antibiotics. Scientists from the Copenhagen Wound Healing ... in Denmark showed that maggots applied to simulated wounds ...
... made of clay and a bit of high-grade plastic draws oil ... lab tests show that oil absorbed can be squeezed back out ... the material, called an aerogel, believe it will effectively clean up ... and roadways, rivers and oceans. , The EPA estimates that 10 ...
Cached Biology Technology:Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board 2Bacteria toxic to wound-treating maggots 2New material absorbs, conserves oil 2
(Date:5/26/2015)... , May 26, 2015 ... the addition of the "Saudi Arabia Biometric ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... is projected to grow at over ... growth is attributed to the surging demand for ...
(Date:5/21/2015)... -- According to a new market ... Services), by Applications (Surveillance (Airborne, Maritime, Land), Threat ... & Defense & Commercial) - Global Forecast to ... expected to grow from $7252.0 Million in 2015 ... Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... abilities to counsel patients on a healthy diet and exercise ... a study by the University of Michigan Cardiovascular Center. ... being overweight, and if the doctor had adequate training in ... published online ahead of print Oct. 1 in Preventive ...
... CITYResearchers at Huntsman Cancer Institute (HCI) at the University of ... the maintenance and repair of the cell,s cytoskeleton, or internal ... cell. The research has implications for cancer, as well as ... with disease. The research was published in the Sep. 14, ...
... N.Y. -- A $634,000 grant from the Department of ... to investigate a trio of environmental factors and their ... two-year project, headed by Murali Ramanathan, PhD, tests the ... metabolism and increased levels of anti-Epstein-Barr virus (EBV) each ...
Cached Biology News:Doctor's health habits affect patient counseling 2Study offers first explanation of how cells rapidly repair and maintain structure 2Gene-environmental interactions and MS progression is focus of new study 2
Request Info...
...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: